Delighted to welcome new investors for 2017, earlier this month Atomo Diagnostics announced backing from Grand Challenges Canada (GCC).
Investment from the Canadian Government-funded agency totalling US$1 million (A$1.31 million, C$1.32 million), in recognition of a ‘bold idea with big impact in global health’, will help Atomo to accelerate development and expand production of pioneering point-of-care diagnostic devices.
Atomo’s award-winning diagnostic products are recognised by key global health partners – including the Global Health Investment Fund, of which GCC is a contributor – for its role in supporting early diagnosis of HIV.
Chairman John Keith explained that as well as recognising the value of Atomo’s contribution to advancing the field of HIV diagnostics, the investment signified Atomo’s ‘commercial potential and continued global growth’.
As news of the investment broke, Atomo’s Chief Commercial Officer Hans Fredman was at the Arab Health trade fair in Dubai, discussing OEM and distributor opportunities with commercial partners in the Middle East.
The year ahead looks set to present new and exciting opportunities for Atomo Diagnostics.